Inhibikase Total Current Liabilities from 2010 to 2024
| IKT Stock | USD 2.92 0.19 6.96% |
Total Current Liabilities | First Reported 2019-12-31 | Previous Quarter 3.7 M | Current Value 4.9 M | Quarterly Volatility 963.6 K |
Check Inhibikase Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibikase Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 89.9 K, Net Interest Income of 935.8 K or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 24.7, Dividend Yield of 0.0 or PTB Ratio of 0.65. Inhibikase financial statements analysis is a perfect complement when working with Inhibikase Therapeutics Valuation or Volatility modules.
Inhibikase | Total Current Liabilities |
Latest Inhibikase Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Inhibikase Therapeutics over the last few years. Total Current Liabilities is an item on Inhibikase Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Inhibikase Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Inhibikase Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibikase Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Inhibikase Total Current Liabilities Regression Statistics
| Arithmetic Mean | 2,655,516 | |
| Geometric Mean | 2,378,077 | |
| Coefficient Of Variation | 47.75 | |
| Mean Deviation | 1,188,733 | |
| Median | 1,726,175 | |
| Standard Deviation | 1,268,080 | |
| Sample Variance | 1.6T | |
| Range | 3.2M | |
| R-Value | 0.82 | |
| Mean Square Error | 562.9B | |
| R-Squared | 0.67 | |
| Significance | 0.0002 | |
| Slope | 232,956 | |
| Total Sum of Squares | 22.5T |
Inhibikase Total Current Liabilities History
About Inhibikase Therapeutics Financial Statements
Inhibikase Therapeutics shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Inhibikase Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Inhibikase Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Inhibikase Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 3.4 M | 3.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.